Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Why should I use sharewise

Sangamo Bioscienes Stock

Price
Target price
€6.24

€6.24

3.400%
0.282
3.400%
€10.99

€10.99

 
Latest predictions
€8.00
29.03.20
buy
€6.00
24.03.20
buy
€8.00
22.03.20
buy
€15.00
02.03.20
buy
-
23.12.19
buy
€23.90
07.08.19
buy
Your prediction

Sangamo Bioscienes Stock

A very strong showing by Sangamo Bioscienes today, with an increase of €0.28 (3.400%) compared to yesterday's price.
Sangamo Bioscienes is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of €10.00 there is a hugely positive potential of 60.359% for Sangamo Bioscienes compared to the current price of €6.24.

Comments

Buy Sangamo Bioscienes

Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about Sangamo Bioscienes Stock

Trading Sangamo Bioscienes

Trading Sangamo Bioscienes

New thread

News

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:




  • Cowen 40th Annual Health Care

Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results


Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights.



“This quarter marked an

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases


Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2019 financial results before

Sangamo Therapeutics Appoints John Markels to Its Board of Directors


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general

Sangamo Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare

Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment


Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND). Pfizer is

Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, is hosting an R&D Day today beginning at 8am Eastern Time. During the event, Sangamo executives and scientists plan to provide

Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the first three patients treated in the Phase 1/2 THALES study evaluating

Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the Phase 1/2 Alta study evaluating

Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo

Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial

Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted

Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at

Sangamo Therapeutics Reports Third Quarter 2019 Financial Results


Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business highlights.



“We continue to prioritize and progress

Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting


Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will

Sangamo Therapeutics Announces New Scientific Advisory Board


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory Board (SAB). The SAB comprises an eclectic group of industry

Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer


Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31